PharmaPoint: Type 2 Diabetes – Global Drug Forecast and Market Analysis to 2026
Summary
Type 2 diabetes (T2D) is a chronic disease characterized by insulin resistance and pancreatic ß-cell failure, with an underlying genetic predisposition heavily influenced by diet and lifestyle (Stumvoll et al., 2010). It is well recognized that many of the current therapies for T2D are generally unable to alter its natural course, with glycemic control typically deteriorating over time. This often results in increasingly complicated treatment regimens (Inzucchi et al., 2012). In the US, T2D is the leading cause of blindness, kidney failure, non-traumatic lower-limb amputations, cardiovascular disease (CVD), and mortality (Sarwar et al., 2010). It is a major cause of heart disease and stroke and is the seventh-leading cause of death among US adults.
Global Type 2 Diabetes (T2D) pharmaceutical market in the base year 2016 was $28.6B, including both branded and generic drugs. Branded products alone accounted for $23.8B across the 7MM. At 71% of the overall T2D market, the US is clearly the dominant market, totaling $20.3B in branded and generic pharmaceutical sales. This is due to the much higher prices of pharmaceuticals in this country and due to the highly diagnosed prevalence of T2D.
Over the forecast period of 2016-2026, the global T2D market will double, reaching $64.0B at a Compound Annual Growth Rate (CAGR) of 8.4%. The US will continue to grow in size most rapidly due to a dramatic increase in T2D prevalence and diagnosis, which is attributed to increased life expectancy and lifestyle changes. The US will increase its global market share from 71% to 74%, stealing market share predominantly from Japan, which will account for 9% of the overall T2D market in 2026. Sales in the US will grow by approximately 8.9% per year over the forecast period.
The report “PharmaPoint: Type 2 Diabetes – Global Drug Forecast and Market Analysis to 2026” focuses on the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), also referred to as the “global market”.
This report provides the following information in-depth –
– Overview of T2D, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
– Annualized T2D therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2016 and forecast for ten years to 2026.
– Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the T2D therapeutics market.
– Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
– Analysis of the current and future market competition in the global T2D therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Companies mentioned in this report: Adocia, Astellas Pharma, AstraZeneca, Biocon, Boehringer Ingelheim, Bristol-Myers Squibb, Chong Kun Dang, Chugai Pharmaceuticals, Daiichi Sankyo, Diasome, Eli Lilly, GlaxoSmithKline, Intarcia Therapeutics, Ionis Pharmaceuticals, Johnson
Scope
– Overview of T2D, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
– Annualized T2D therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2016 and forecast for ten years to 2026.
– Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the T2D therapeutics market.
– Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
– Analysis of the current and future market competition in the global T2D therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to –
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
– Develop business strategies by understanding the trends shaping and driving the global T2D therapeutics market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global T2D therapeutics market in future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Track drug sales in the global T2D therapeutics market from 2016-2026.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.